Quantcast

AMT Starts Development LPLChip(TM) With Progenika

October 29, 2009

AMSTERDAM, October 29 /PRNewswire-FirstCall/ — Amsterdam Molecular
Therapeutics (AMT) and Progenika Biopharma announced today that the companies
have entered into a development and commercialization agreement for
LPLchip(TM), a diagnostic tool to rapidly diagnose patients with complete and
partial lipoprotein lipase deficiency (LPLD). AMT has developed Glybera(R) as
a gene therapy for patients with this disease.

In June of this year AMT announced new clinical data showing that a
one-time administration of its lead product Glybera(R) results in significant
long-term health benefits for LPLD patients. Long-term follow-up data from
two clinical trials with complete LPLD patients show that Glybera(R) therapy
results in a significant and clinically important reduction in acute
pancreatitis, the most debilitating complication of the disease. The data
also confirm that the therapy is well-tolerated and safe. AMT intends to file
Glybera(R) for marketing approval with EMEA by the end of this year.

LPLchip(TM) based on the Progenika’s DNA-chip technology, will be used to
rapidly diagnose patients with complete and partial LPLD and will be
important to effectively identify patients that could benefit from Glybera
(R).

AMT has selected Progenika as a partner for the development of
LPLchip(TM) because of the company’s long-standing expertise in the
development of diagnostic chips and its access to both European and North
American markets. Jorn Aldag, CEO of AMT commented: “We are delighted to work
with Progenika on the development of the LPLchip(TM), as the company brings a
unique expertise that fits the diagnostic needs for LPLD. LPLchip(TM) will be
an important tool in early patient diagnosis, enabling us to make Glybera(R)
available to the right patients as quickly as possible.” Antonio Martinez,
CEO of Progenika Biopharma said: “This collaborative project demonstrates how
DNA-based diagnostics and highly targeted gene therapy can be combined to
bring personalized medicine to patient groups whose medical needs were
previously unmet.”

About Progenika

PROGENIKA, a pioneering company in the emerging field of personalised
medicine, is dedicated to the design, development and manufacture of novel
DNA genotyping microarrays for the diagnosis, prognosis and drug-response
prediction of complex human diseases. The company’s comprehensive facilities
for microarray design and manufacture are supported by an expert team of
bioinformaticians who develop multivariate algorithms and software packages
that allow user-friendly interpretation of clinical results. PROGENIKA has
developed and clinically validated LIPOchip, a microarray for the diagnosis
of Familial Hypercholesterolemia that was marketed in 2004, as the first
CE-marked DNA microarray for routine clinical diagnosis. PHARMAchip, a Drug
Metabolism genotyping microarray and BLOODchip, a Blood Group genotyping
microarray were launched in 2007. A series of new diagnostic microarrays are
under development or in late-stage clinical validation: fibromyalgia,
inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis,
osteoarthritis, etc.

About Amsterdam Molecular Therapeutics

AMT has a unique gene therapy platform that to date appears to circumvent
many if not all of the obstacles that have prevented gene therapy from
becoming a mainstay of clinical medicine. Using adeno-associated viral (AAV)
vectors as the delivery vehicle of choice for therapeutic genes, the company
has been able to design and validate what is probably the first stable and
scalable AAV production platform. As such, AMT’s proprietary platform holds
tremendous promise for thousands of rare (orphan) diseases, especially those
that are caused by one faulty gene. Currently, AMT has a product pipeline
with nine products at different stages of development.

Certain statements in this press release are “forward-looking statements”
including those that refer to management’s plans and expectations for future
operations, prospects and financial condition. Words such as “strategy,”
“expects,” “plans,” “anticipates,” “believes,” “will,” “continues,”
“estimates,” “intends,” “projects,” “goals,” “targets” and other words of
similar meaning are intended to identify such forward-looking statements.
Such statements are based on the current expectations of the management of
Amsterdam Molecular Therapeutics only. Undue reliance should not be placed on
these statements because, by their nature, they are subject to known and
unknown risks and can be affected by factors that are beyond the control of
AMT. Actual results could differ materially from current expectations due to
a number of factors and uncertainties affecting AMT’s business, including,
but not limited to, the timely commencement and success of AMT’s clinical
trials and research endeavors, delays in receiving U.S. Food and Drug
Administration or other regulatory approvals (i.e. EMEA, Health Canada),
market acceptance of AMT’s products, effectiveness of AMT’s marketing and
sales efforts, development of competing therapies and/or technologies, the
terms of any future strategic alliances, the need for additional capital, the
inability to obtain, or meet, conditions imposed for required governmental
and regulatory approvals and consents. AMT expressly disclaims any intent or
obligation to update these forward-looking statements except as required by
law. For a more detailed description of the risk factors and uncertainties
affecting AMT, refer to the prospectus of AMT’s initial public offering on
June 20, 2007, and AMT’s public announcements made from time to time.

SOURCE Amsterdam Molecular Therapeutics B.V


Source: newswire



comments powered by Disqus